Oslo, Norway, 1 October 2018: Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference:

13th International Adenovirus Meeting
Date: 27 September 2018
Presenter: Lukasz Kuryk, Director Clinical Science
Poster session: 20:00 - 23:00
Venue: San José Vista Hermosa, Mexico
Abstract title: Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model.

1809 Poster ONCOS-102 @ http://mb.cision.com/Public/17093/2632463/b0f3bb45e90575ef.pdf